Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CINC-1 binding to Syndecan-1
- Molecular classification
- Chemokine, CXC chemokine family, Cell surface heparan sulfate proteoglycan, Transmembrane protein
01
Overview
CINC-1 (CXCL1) is a small chemokine peptide functioning as a potent neutrophil chemoattractant and an acute-phase protein, particularly in the context of tissue injury and inflammation. Syndecan-1 is a transmembrane heparan sulfate proteoglycan that plays multiple roles in cell adhesion, migration, matrix remodeling, and acts as a coreceptor for growth factors and chemokines. Binding between chemokines (such as CINC-1/CXCL1) and Syndecan-1 occurs via the heparan sulfate chains on Syndecan-1 and modulates cell signaling, leukocyte recruitment, and tissue responses to injury. Altered expression and modification of Syndecan-1 are implicated in cancer progression, tissue remodeling, and inflammatory diseases
- Other names
- CXCL1KCGRO-αNeutrophil-activating protein-3 (NAP-3)Melanoma growth stimulating activity alpha (MGSA-α)SDC1CD138
02
Mechanism of action
Chemokine inhibitors block neutrophil recruitment and inflammatory signaling via CXCL1-CXCR2 pathway. Syndecan-1 blockade or modulation may disrupt growth factor signaling, tumor cell adhesion, and matrix remodeling
03
Biological functions
Neutrophil chemoattractionregulation of immune and inflammatory responseswound healingtumorigenesisCell proliferationcell migrationcell-matrix interactionsmatrix remodelingcell signalingcoreceptor for growth factors
04
Disease associations
Inflammationmultiorgan dysfunction (MODS)infectionpotentially cancerCancer (e.g., myeloma, breast, colon, prostate)cardiovascular diseaseinflammationwound healing
05
Safety considerations
Impairing normal immune response, tissue repair, and homeostasis due to targeting chemokines or proteoglycansAltering wound healing and matrix remodeling due to blocking Syndecan-1Blunting host defense due to chemokine inhibition
06
Interacting drugs
CXCR2 antagonists (targeting chemokine-receptor axis)
2 more in the full profile.
07
Biomarkers
Syndecan-1 levels (CD138) are used as a biomarker in plasma cell neoplasms (e.g., multiple myeloma), and may serve as a marker in other tumorsCXCL1 (CINC-1) levels can be indicative of inflammatory responses and acute phase reactions
Beyond the preview
Go deeper on CINC-1 binding to Syndecan-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CINC-1 binding to Syndecan-1.